Glass House Brands (GLAS) Current Assets (2020 - 2026)
Glass House Brands' (GLAS) quarterly Current Assets came in at $74.4 million in Q1 2026, up 8.47% year-on-year from $68.5 million in Q1 2025, and up 9.75% on a QoQ basis from $67.7 million in Q4 2025.
Glass House Brands (GLAS) Current Assets (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Current Assets data on file, last reported at $74.4 million in Q1 2026.
- On a quarterly basis, Current Assets rose 8.47% year-over-year to $74.4 million in Q1 2026; TTM through Mar 2026 was $74.4 million, a 8.47% increase from a year earlier, with the FY2025 full-year figure at $67.7 million, up 2.49% from the prior year.
- Current Assets for Q1 2026 stood at $74.4 million, up from $67.7 million in the prior quarter.
- Over the last five years, Current Assets for GLAS reached as high as $86.5 million in Q2 2025 and fell as low as $37.9 million in Q1 2023.
- Historically, Current Assets has averaged $56.8 million across 5 years, with a median of $52.5 million in 2024.
- Across the five-year window, Current Assets slumped 70.95% in 2022 and jumped 64.87% in 2025, its largest moves.
- Year by year, Current Assets stood at $38.9 million in 2022, then gained by 26.54% to $49.2 million in 2023, then soared by 34.31% to $66.1 million in 2024, then climbed by 2.49% to $67.7 million in 2025, then gained by 9.75% to $74.4 million in 2026.
- Per Business Quant data, the three most recent Current Assets figures were $74.4 million in Q1 2026, $67.7 million in Q4 2025, and $74.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 6.05 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.71 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 6.47 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 19.71 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 2.87 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 6.53 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 10.92 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2.44 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 3.58 Bn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 74.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.35 Mn |
| Dec 31, 2025 | 67.75 Mn |
| Sep 30, 2025 | 74.34 Mn |
| Jun 30, 2025 | 86.50 Mn |
| Mar 31, 2025 | 68.55 Mn |
| Dec 31, 2024 | 66.10 Mn |
| Sep 30, 2024 | 67.33 Mn |
| Jun 30, 2024 | 52.47 Mn |
| Mar 31, 2024 | 42.08 Mn |
| Dec 31, 2023 | 49.22 Mn |
| Sep 30, 2023 | 59.67 Mn |
| Jun 30, 2023 | 47.30 Mn |
| Mar 31, 2023 | 37.86 Mn |
| Dec 31, 2022 | 38.89 Mn |
| Sep 30, 2022 | 45.26 Mn |
| Jun 30, 2022 | 44.74 Mn |
| Mar 31, 2022 | 42.56 Mn |
| Dec 31, 2021 | 68.62 Mn |
| Sep 30, 2021 | 50.51 Mn |
| Jun 30, 2021 | 154.00 Mn |